Taysha Gene Therapies, Inc. (TSHA)

NASDAQ: TSHA · IEX Real-Time Price · USD
2.68
0.06 (2.29%)
May 27, 2022 4:00 PM EDT - Market closed
Market Cap108.66M
Revenue (ttm)n/a
Net Income (ttm)-192.61M
Shares Out40.55M
EPS (ttm)-5.08
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume266,444
Open2.62
Previous Close2.62
Day's Range2.55 - 2.76
52-Week Range2.33 - 26.99
Betan/a
AnalystsBuy
Price Target29.78 (+1,011.2%)
Earnings DateMay 16, 2022

About TSHA

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies,...

IndustryBiotechnology
IPO DateSep 24, 2020
Employees178
Stock ExchangeNASDAQ
Ticker SymbolTSHA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 22 analysts, the average rating for TSHA stock is "Buy." The 12-month stock price forecast is 29.78, which is an increase of 1,011.19% from the latest price.

Price Target
$29.78
(1,011.19% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Taysha Gene Therapies Reports First Quarter 2022 Financial Results and Provides Corporate Update

Initiated clinical development of TSHA-102 for Rett Syndrome under recently approved Clinical Trial Application (CTA) with preliminary Phase 1/2 data expected by year-end 2022

1 week ago - GlobeNewsWire

Taysha Gene Therapies to Release First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 16

DALLAS, May 11, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therap...

2 weeks ago - GlobeNewsWire

Taysha Gene Therapies Announces Presentations at the Upcoming 25th Annual Meeting of the American Society of Gene & C...

DALLAS, May 10, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therap...

2 weeks ago - GlobeNewsWire

Taysha Gene Therapies Receives Orphan Drug Designation from the European Commission for TSHA-120 for the Treatment of...

Clinical efficacy data for TSHA-120 provide quantitative evidence of long-term durability across all therapeutic dose cohorts with a 10-point improvement in mean change in MFM32 by Year 3 compared to es...

3 weeks ago - GlobeNewsWire

Taysha Gene Therapies Announces Oral Presentations at the Upcoming 2022 IRSF Rett Syndrome Scientific Symposium and t...

DALLAS, April 25, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene ther...

1 month ago - GlobeNewsWire

Taysha Gene Therapies to Participate in Upcoming Chardan Genetic Medicines and Cell Therapy Manufacturing Summit

Chief Executive Officer, Chief Technical Officer, Chief Medical Officer and Head of Research and Development and Senior Vice President of Manufacturing to participate in a panel discussion at the Charda...

1 month ago - GlobeNewsWire

Wall Street Analysts Believe Taysha Gene Therapies, Inc. (TSHA) Could Rally 608%: Here's is How to Trade

The consensus price target hints at a 608.2% upside potential for Taysha Gene Therapies, Inc. (TSHA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in...

1 month ago - Zacks Investment Research

Taysha Gene Therapies Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the trea...

1 month ago - Business Wire

Taysha Gene Therapies Announces Initiation of Clinical Development of TSHA-102 in Rett Syndrome

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the trea...

1 month ago - Business Wire

Taysha Gene Therapies to Release Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call and Web...

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the trea...

2 months ago - Business Wire

Taysha Gene Therapies to Participate in Upcoming April Investor Healthcare Conferences

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the trea...

2 months ago - Business Wire

Taysha Gene Therapies to Participate in the Oppenheimer 32nd Annual Virtual Healthcare Conference

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the trea...

2 months ago - Business Wire

Two Insider Moonshots Rising on Sudden Buying

Biotech insiders are among the most important investors to pay close attention to. Here are two that show good signs for the future.

Other symbols:HROW
3 months ago - InvestorPlace

Taysha Gene Therapies Announces Positive Safety Data from UT Southwestern-Sponsored Clinical Trial for the Treatment ...

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the trea...

3 months ago - Business Wire

Taysha Reports Efficacy, Safety Data From High Dose Cohort For Neurological Disorder Gene Therapy Trial

Taysha Gene Therapies Inc TSHA has reported clinical efficacy and safety data for the high dose cohort of 3.5x1014 total vg and long-term durability data across all therapeutic doses of TSHA-120 in gian...

3 months ago - Benzinga

Taysha Gene Therapies Reports Positive Clinical Efficacy and Safety Data for High Dose Cohort and Long-term Durabilit...

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the trea...

3 months ago - Business Wire

Taysha Gene Therapies Announces Positive Initial Biomarker Data For TSHA-101, the First Bicistronic Gene Therapy in C...

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the trea...

4 months ago - Business Wire

Taysha Gene Therapies to Present at the 40th Annual J.P. Morgan Healthcare Conference

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the trea...

4 months ago - Business Wire

Taysha Gene Therapies to Participate in Panel Discussions at the LifeSci Partners 11th Annual Corporate Access Event

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the trea...

4 months ago - Business Wire

Taysha Gene Therapies Announces January 2022 Virtual Investor Events to Review Preliminary Clinical Data for TSHA-101...

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the trea...

4 months ago - Business Wire

Taysha Gene Therapies Added to the ICE Biotechnology Index

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the trea...

5 months ago - Business Wire

Taysha Gene Therapies Announces Positive Preliminary Clinical Safety Data For First-Generation Construct In CLN7 Dise...

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the trea...

5 months ago - Business Wire

Taysha Gene Therapies Announces Initiation of Clinical Development of TSHA-118 for the Treatment of CLN1 Disease

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the trea...

5 months ago - Business Wire

Taysha Gene Therapies Added to the Nasdaq Biotechnology Index

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the trea...

5 months ago - Business Wire

Taysha Gene Therapies Announces Late-Breaking Abstract and Poster Presentation on Positive Preclinical Data For TSHA-...

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the trea...

5 months ago - Business Wire